Deregulation of the pRb/E2F or Wnt/b-catenin pathway occurs frequently in human cancers, which is often associated with inappropriate cell proliferation. Although the oncogenic roles of pRb/E2F1 and Wnt/b-catenin pathways have been well studied, the functional interaction between the two pathways has only recently been characterized. In particular, E2F1 has been recently reported to negatively regulate Wnt/b-catenin activity in human colorectal cancers, though the mechanism underlying this regulation is not fully understood. Here we provide evidence that b-catenin interacting protein 1 (CTNNBIP1), also known as ICAT (inhibitor of b-catenin and TCF4), functions as a crucial node to mediate the cross talk between E2F1 and b-catenin signaling. We show that ICAT is a direct transcriptional target of E2F1, and that activation of ICAT by E2F1 is required for E2F1 to inhibit b-catenin activity. This study provides a mechanistic insight into the antagonistic interaction between E2F1 and b-catenin signaling.
Introduction
Wnt/b-catenin signaling regulates the stability and subcellular localization of transcription factor b-catenin and therefore b-catenin-dependent gene expression (Logan and Nusse, 2004; Clevers, 2006; Polakis, 2007; Klaus and Birchmeier, 2008) . Deregulation of the Wnt/ b-catenin pathway has been implicated in human malignance, owing to the genetic or epigenetic alterations in negative or positive regulators of Wnt/b-catenin components, which leads to aberrant activation of its target genes, such as c-MYC and CyclinD1, promoting cell growth, tissue invasion or metastasis (Moon et al., 2004; Clevers, 2006; Cadigan, 2008; Klaus and Birchmeier, 2008) . On the other hand, genetic inactivation of RB pathway due to RB mutation or alterations in other upstream regulators (such as CyclinD1, Cdk4 or p16) may lead to aberrant activation of another transcription factor E2F1, leading to deregulation of Rb/E2F1 in a variety of human cancers (Sherr and McCormick, 2002) . Unlike Wnt/b-catenin signaling, E2F1 is also equipped with an ability to induce apoptosis, suggesting a potential tumor suppressor function of E2F1. Obviously, the paradoxical behavior of E2F1 as an oncogene or as a tumor suppressor is operated in a context-dependent manner.
Compared with other human cancers, a long-standing puzzle in most colorectal cancers is the observation that while Wnt/b-catenin signaling is activated, E2F1 activity is kept at a low level as there are rare mutations in Rb, as opposed to some 30% inactivation or mutation rate of Rb in other human cancers (Nevins, 2001) . Moreover, instead of acting as an oncogene, E2F1 in human colorectal cancers may function as a tumor suppressor and the lower level of E2F1 expression is more correlated with a poor disease outcome (Bramis et al., 2004) . Recently, E2F1 activity in colorectal cancer was reported to be inhibited by CDK8 (Morris et al., 2008) , an oncogene amplified in 50% of colorectal cancers (Firestein et al., 2008) , leading to activation of b-catenin activity (Morris et al., 2008) . These studies reveal a cross talk between the two critical signaling pathways in colorectal cancers and further support a tumor suppressor role of E2F1 in colorectal cancers by negatively regulating b-catenin pathway (Bernards, 2008) . Mechanistically, several E2F1 targets such as Axin1/2 and SIAH1 have been implicated in this process (Firestein et al., 2008; Morris et al., 2008; Xie, 2009) . In this study, we seek to further understand the mechanistic insights into E2F1 regulation of Wnt/b-catenin activity and identify b-catenin interacting protein 1 (CTNNBIP1), also known as ICAT (inhibitor of b-catenin and TCF4), as a key E2F1 target mediating this effect of E2F1.
Results and discussion

E2F1 regulates CTNNBIP1 (ICAT) expression
To identify the E2F1 targets that are responsible for E2F1-mediated inhibition of Wnt/b-catenin signaling, we used human osteosarcoma Saos-2 cells that express an inducible ER (estrogen receptor)-E2F1 fusion protein.
In this system, E2F1, which is fused to the hormonebinding domain of human estrogen receptor, moves from the cytoplasm to the nucleus upon addition of estrogen receptor ligand 4-hydroxytamoxifen (hereafter referred to as OHT) and activates the expression of its target genes (Vigo et al., 1999) . To identify E2F1-regulated genes, we used the Illumina Huamn Ref-8_V2 Sentrix BeadChip (Illumina, San Diego, CA, USA) to compare the transcriptional profile between Saos-2 cells expressing ER-E2F1 and the empty vector (pBabe) that were treated with OHT for 8, 24, or 48 h. As shown in a gene expression heatmap of representative E2F1-responsive genes (Figure 1a) , OHT treatment of Saos-2 ER-E2F1 cells resulted in significant induction (X3 fold) of many well-known E2F1 target genes, including CCNA1, CCNE1/2, BCL2L11, APAF-1, CASP3, CASP9 and EZH2 (Bracken et al., 2003; Zhao et al., 2005; Iaquinta and Lees, 2007; Polager and Ginsberg, 2008) in a timedependent manner. Consistent with an inhibitory role of E2F1 on Wnt/b-catenin signaling, we observed the downregulation of a number of Wnt/b-catenin target genes, including CCND1, c-MYC, MMP7, BMP4, ACCN1 and IL8 (Figure 1a ). Among OHT-responsive genes, we noticed that CTNNBIP1, which encodes a b-catenin-interacting protein (ICAT), was markedly induced in an E2F1-dependent manner (Figure 1a or an empty vector (pBabe) were treated with OHT (300 nM) for the indicated time points. Total RNA was extracted using TRizol (Invitrogen, Carlsbad, CA, USA) and purified with the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Reverse transcription was performed using an RNA Amplification kit (Ambion, Austin, TX, USA). The microarray hybridization was performed using the Illumina Gene Expression Sentrix BeadChip HumanRef-8_V2 (Illumina, San Diego, CA, USA), and data analysis was performed and viewed using GeneSpring software from Agilent Technologies (Agilent, Santa Clara, CA, USA). Red, genes with higher expression levels; green, genes with lower expression levels. (b) ICAT, SIAH1 and CCNE1 mRNA expression levels in Saos-2 ER-E2F1 cells upon E2F1 activation. Saos-2 ER-E2F1 or pBabe control cells were treated with OHT (300 nM) for 24 h and the total RNA was isolated as in (a). Quantitative real-time PCR (qRT-PCR) was performed on a PRISM 7900 Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA) using TaqMan probes of ICAT, SIAH1 and CCNE1 (Applied Biosystems). Samples were normalized to the levels of 18S ribosomal RNA. E2F1 suppresses Wnt/b-catenin activity through ICAT Z Wu et al repression of b-catenin-TCF4-mediated transactivation (Tago et al., 2000) . Quantitative reverse transcription-PCR validated the array data and showed that E2F1 activation by OHT induced the expression of ICAT in a level similar to the bona fide E2F1 target CCNE1 (Figure 1b ), which was accompanied by the reduced expression of b-catenin targets c-MYC and CCND1 ( Figure 1c ). SIAH1, a previously reported E2F1 target that can inhibit b-catenin activity as shown in lung cancer H1299 cells (Xie, 2009) , was only modestly induced by E2F1 activation in our system (Figure 1b) . Furthermore, a DNA-binding defective mutant of E2F1 (E132) was unable to induce ICAT expression (Figure 1d ), and E2F1-induced expression of ICAT mRNA was not affected by the protein synthesis inhibitor cycloheximide, as demonstrated in both Saos-2 ER-E2F1 and HCT116 ER-E2F1 cells (Figure 1d ). These findings suggest that ICAT might be a direct target of E2F1. Finally, western blot analysis confirmed the induction of ICAT protein expression by E2F1, but not by E132, in ER-E2F1-expressing Saos-2 and HCT116 cells (Figure 1e ). We next sought to investigate whether ICAT expression is regulated by endogenous E2F1. To this end, we first compared the expression levels of ICAT between the human lung fibroblast IMR90 cells and IMR90 cells transformed by the oncoprotein E1A. E1A is known to inactivate Rb family members, which leads to the activation of endogenous E2F1 (Nahle et al., 2002) . Indeed, IMR90/E1A cells express much more CCNE1 and ICAT at both transcription and protein levels as compared with control IMR90 cells (Figure 2a) . Furthermore, siRNA-mediated knockdown of E2F1 in IMR90/E1A cells resulted in marked decrease of ICAT mRNA and protein expression (Figure 2b ), confirming the regulation of ICAT expression by the endogenous E2F1. To further substantiate this conclusion, we arrested Saos-2 in G0/G1 phase by serum starvation and then released cells into the cell cycle by addition of serum (Figure 2c ). Western blot in Figure 2d shows that while the serum-starved Saos-2 cells reentered the cell cycle following the addition of serum, E2F1 expression was elevated over time, which was accompanied by increased expression of cyclinE1 and ICAT (Figure 2d ). Taken together, these findings demonstrate that both the exogenous and endogenous E2F1 regulate ICAT expression.
ICAT is a direct binding target of E2F1 Sequence analysis identified three putative E2F1-binding sites (À1769/À1762, À402/À395 and À234/À226) in the proximal region of the ICAT promoter (Figure 3a ). This encourages a hypothesis that E2F1 may activate ICAT transcription by binding to its promoter. To test this, three ICAT promoter fragments were isolated and subcloned into a luciferase reporter plasmid and their E2F1 suppresses Wnt/b-catenin activity through ICAT Z Wu et al response to ectopic E2F1 expression was examined. The results show that ICAT promoter fragment containing two putative E2F1-binding sites within the genomic region of À500/ þ 56 (fragment 1, F1) can be markedly activated by E2F1, but not by E132, in a dosedependent manner (Figure 3b ). Of note, this activation of ICAT promoter seemed to be more robust than the Bim promoter, which was used here as a positive control (Tan et al., 2006) . Extension of the promoter region to include the distal E2F1-binding site (F2, À2000/ þ 56) did not seem to provide additional response to E2F1, indicating that the core promoter region between À500 and þ 56 is sufficient to give rise to a full E2F1 response. The upstream promoter region between À2000 and À1000 (F3) did not respond to E2F1 (Figure 3b ). We next determined whether E2F1 can directly bind to the ICAT gene promoter. We performed chromatin immunoprecipitation assay using anti-E2F1 antibody in Saos-2 ER-E2F1, E132 mutant or pBabe cells, followed by quantitative PCR using primer sets flanking the putative E2F1-binding sites in the core promoter region (B500 bp upstream of the transcription start site) and the distal E2F1 site (B1.76 kb upstream of the transcription start site). The results show that upon OHT treatment E2F1 binds strongly to the ICAT core promoter region, which was not seen in pBabe or E132 cells (Figure 3c ). By contrast, no enrichment of E2F1 was found in the region containing the distal E2F1-binding site. In view of these results, we conclude that ICAT is a direct transcriptional target of E2F1.
ICAT induction is required for the E2F1-mediated inhibition of b-catenin activity To determine whether ICAT induction by E2F1 is functionally required for E2F1-mediated inhibition of b-catenin activity, we performed a series of experiments to examine the effect of ICAT on the b-catenin-TCF4 reporter activity in the context of E2F1. It is well known that colon cancer cells express constitutively activated b-catenin due to either adenomatous polyposis coli (APC) or b-catenin mutations (Morris et al., 2008) . In both colon cancer HCT116 and SW480 cells, ectopic expression of E2F1 or ICAT results in marked inhibition of b-catenin/TCF4 activity, as determined by TCF4-dependent luciferase reporter activity (Figure 4a HCT116 cells were transfected with empty vector pcDNA4, pcDNA4-E2F1 (50 or 100 ng) or a mutant E2F1 expression plasmid, pcDNA4-E132 (50 or 100 ng), together with pGL3 promoter luciferase construct pGL3 (100 ng, Promega, Madison, WI, USA) containing the indicated ICAT promoter regions as shown in (a). Relative luciferase activities were measured 48 h after transfection.
Results were presented as fold induction after normalization to Renilla luciferase activity. Bim promoter (pGL3-Bim) that contains the predicted E2F-binding sites described previously was used as a positive control (Zhao et al., 2005) . All experiments were performed at least twice in triplicate. (c) Chromatin immunoprecipitation analysis of the physical association between E2F1 and the ICAT promoter region in vivo. Saos-2 cells infected with an empty retrovirus (pBabe), or a retrovirus expressing either wild-type E2F1 (ER-E2F1) or a mutant ER-E2F1 (E132) were left untreated (À) or treated with OHT (300 nM) for 24 h. Crosslinked protein-chromatin complexes were immunoprecipitated by using antibodies against E2F1(c-20, Santa Cruz) or a non-specific IgG control (sc-2027, Santa Cruz) as described previously (Wu et al., 2010) . The immunoprecipitated DNA was quantitated by real-time PCR using the PRISM 7900HT Fast Real-Time PCR System (Applied Biosystems). The enrichment of specific genomic regions was assessed relative to the input DNA (mean ± s.d. of triplicate measurements).
E2F1 suppresses Wnt/b-catenin activity through ICAT Z Wu et al of ectopic E2F1 or ICAT in HCT116 and SW480 cells showed that ICAT is a much more robust inhibitor of b-catenin/TCF4 activity than E2F1 (Figure 4b ), indicating that ICAT might be a key E2F1 target mediating this effect. Furthermore, as b-catenin is negatively regulated by GSK-3b, which can be relieved by applying GSK-3b inhibitor LY2119301, we next tested whether ectopic E2F1 or ICAT can also abolish GSK-3b inhibitor-activated b-catenin in Saos-2 and HEK293 cells. As shown in Figure 4c , treatment with GSK-3b inhibitor LY2119301 induced a dramatic activation of b-catenin activity in these cells, which was completely abolished by ectopic expression of E2F1 or ICAT (Figure 4c ). In addition to ICAT, the array data shows that E2F1 also induces the expression of AXIN1, AXIN2 and SIAH1, which might also act as negative regulators of b-catenin activity (Morris et al., 2008; Xie et al., 2009 ). ICAT siRNA no. 1 was obtained from Sigma-Proligo targeting the following sequence: 5 0 -GATATCAACAGCTTCCCTATT-3 0 . ICAT siRNA no. 2 and the non-targeting control siRNA were purchased from Dharmacon (Lafayett, CO, USA). Specific AXIN2 siRNA was described previously (Kim et al., 2009) . (e) Saos-2 ER-E2F1 cells transfected with negative control, AXIN2 or ICAT siRNA (no. 1) were treated with small-molecule GSK3-b inhibitor LY2119301 (GSKi, 1 mM), followed by transfection with 100 ng of luciferase reporter plasmids in the presence or absence of OHT (300 nM). pTopFLASH luciferase activity and western blot were conducted as in (d).
E2F1 suppresses Wnt/b-catenin activity through ICAT Z Wu et al
It is worthwhile to note that the expression levels of AXIN2 and ICAT were induced by OHT as early as 8 h, which was sustained for up to 48 h. This induction kinetic was inversely correlated with the kinetics of CCND1 and c-MYC downregulation (Figure 1a) . By contrast, AXIN1 was not found to be induced by E2F1 in this system and SIAH1 was only modestly induced at 48 h (Figures 1a and b) . This suggests that the inhibition of b-catenin signaling following E2F1 activation is more likely to be associated with the induction of AXIN2 or ICAT.
Furthermore, given that ectopic E2F1 can effectively abolish GSK-3b inhibitor-induced b-catenin activity, we reasoned that the E2F1 target responsible for the inhibition of b-catenin activity should act downstream of GSK3b, which thus does not favor a role of AXIN2 in this process. To further validate this hypothesis, we depleted AXIN2 or ICAT and the corresponding effects on E2F1-mediated inhibition of b-catenin activity were examined accordingly. In SW480 cells, the inhibitory effects of ectopic E2F1 on active b-catenin, as shown by western blot (Figure 4d , lower panel), as well as on the TCF4-luciferase reporter activity (Figure 4d , upper panel), were completely rescued by concomitant knockdown of ICAT, whereas AXIN2 knockdown had no such effect (Figure 4d ). Likewise, in Saos-2 ER-E2F1 cells, ICAT knockdown also abolished the inhibitory effect of E2F1 on GSK-3b inhibitor-induced b-catenin activity, whereas AXIN2 knockdown only had a modest effect (Figure 4e ). Intriguingly, ICAT knockdown overshot the GSK inhibitor-induced activation of b-catenin, indicating that in Saos-2 cells b-catenin activity is already repressed by ICAT, probably due to the Rb loss and thus a higher E2F1 activity in this cell line. These findings demonstrate an active role of ICAT, but not necessarily the AXIN2, in E2F1-mediated inhibition of b-catenin activity. We thus conclude that ICAT is a key transcriptional target of E2F1 that is responsible for the suppression of b-catenin activity.
In summary, our data demonstrates a mechanistic link between Rb/E2F1 pathway and Wnt/b-catenin through ICAT, an inhibitor of Wnt/b-catenin activity. They further support a notion that E2F1 can have a tumor suppressor role in colorectal cancer by antagonizing Wnt/b-catenin activity. Given the relatively lower activity of E2F1 in colorectal cancer (Nevins, 2001) , it suggests that development of therapeutics that can activate the E2F1-ICAT function might be useful for colorectal cancer treatment.
